TotipotentRX Bone Marrow Transplant and Cell Therapy Services (India)

Bone Marrow  Transplant  and Cell Therapy Services

The Fortis-TotipotentRX Center for Cellular Medicine and GMP clinical laboratory team is located inside the Oncology Department of Fortis Memorial Research Institute (Gurgaon – National Capital Region).  This unique collaborative atmosphere of combining our advanced scientific staff and Fortis’ globally recognized hematology/oncology team is rapid advancement of new protocols and services to our  partners. TotipotentRX facility provides laboratory services and scientific support  which employs a proprietary approach to bone marrow  transplant and cellular therapy using the  AutoXpress AXP® and MarrowXpress MXP® platforms when the processing of the donor’s mobilized peripheral blood or bone marrow is required. These technologies allow for a proprietary transplant approach that increases pediatric patient access to this life saving treatment by enabling the following types of transplants that might otherwise not be an option for the patient. Contact information.

Services We Provide to India


ABO Major (and Minor) Mismatch BMTs

  • RBC & Plasma reduction (depletion) protocols
  • Cryo-preservation of Bone Marrow Units
  • Cell Diagnostic Services

Haploidentical BMTs

  • Bone Marrow Purification (volume reduction without target cell depletion)
  • RBC & Plasma reduction (depletion) protocols
  • Cryo-preservation of Bone Marrow Units
  • Cell Diagnostic Services
  • Ex vivo haplo-identical bone marrow preparation

Clinical Trials

1.   Haploidentical unmatched related donor program

*Only available in India.

Our  clinical research and development division is the only specialized, in-hospital, cell therapy CRO globally. We leverage Cesca’s unique expertise in designing, managing, and completing cell based clinical trials. . The services offered ensure patient safety under Good Clinical Practices (GCP), quality laboratory documentation under Good Laboratory Practices (GLP), and quality cell processing and handling under both Good Manufacturing Practices (GMP) and Good Tissue Practices (GTP).

Cord Blood Banking

Cord blood banking is the process of collecting the blood from a newborn’s umbilical cord immediately after delivery and cryogenically storing it for future potential medical uses.

NovaCord  is a collaborative enterprise between   Cesca Therapeutics/TotipotentRX and Fortis Healthcare.  The NovaCord bank and Center for Cellular Medicine is placed within the newly constructed superspecialty and advanced care Fortis Gurgaon hospital, where expertise is available for both banking stem cells and treating patients using advanced cellular therapy procedures. Our scientific and clinical teams seamlessly integrate their clinical expertise in oncology, neurology, endocrinology, cardiology, and orthopedics with more than fifteen years of cord blood banking science. For more information on services in India  contact Novacord in India.

Our Strengths and Technology

TotipotentRX is a subsidiary of Cesca Therapeutics Inc. (USA “NASDAQ: KOOL”), a leading cell therapy company engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine.  Our  lead therapeutic technology platform, SurgWerks® is currently in various stages of clinical trials for cellular therapy. Providing point-of-care treatment, this platform brings  technology that can harvest, process and deliver cell therapy  to the patient within one hour. The SurgWerks Platform provides:

  • Rapid (60-90 minute) use at the bedside
  • Integrated protocol, devices and disposables to produce the specified autologous therapeutic cell dos

Our products and services provide innovative technologies for:

  • Processing and Delivery of Cellular Therapeutics
  • Cell Manufacturing and Bio-banking
  • Clinical Research and Development for Cellular Therapy

Find out more about bone marrow transplants.


Venkatesh Ponemone | Executive Director of India Operations, Director of Clinical and Scientific Affairs (TotipotentRX Cell Therapy Pvt. Ltd.)


Dr. Ponemone serves as the Executive Director of Indian operations and Director, Clinical and Scientific Affairs since September 2008.  Prior to joining TotipotentRX, he was an Assistant Professor of Medical Microbiology at Kamineni Graduate School of Medicine, Hyderabad, India.  Dr. Ponemone completed a two year post-doctoral position in inflammation immunology at the University of Illinois, Chicago, and authored more than 28 peer reviewed publications on topics like regenerative medicine, role of cytokines in autoimmune disease, radioprotective and chemoprotective agents in cancer treatment.  Dr. Ponemone is a Fellow of Academic General Education, and has a Ph.D. from Manipal University in radiation therapy and oncology, holds a post-graduate degree in Medical Microbiology from Kasturba Medical College, Manipal University and also holds a Master’s in Business Administration. His primary  responsibility is to oversee cGMP Cell processing Core Facility for Stem Cell Transplant and Regenerative Medicine Program at the Centre for excellence in Cellular Medicine at Fortis Hospital, Gurgaon. He is also responsible for overall clinical trial planning and management, and manage all aspects of clinical development.

Dr. Namita Mathur, MD / Medical Director